Summary

ephedrine

In 1887 Nagajoshi Nagai (1845-1929), a Japanese researcher working in Germany, isolated ephedrine as the active ingredient of ma huang but found the substance to be highly toxic. In the 1920s, Chinese pharmacologist Ko Kuei Chen (1898-1988) and American pharmacologist Carl F. Schmidt (1893-1965), working at Peking Union Medical College, isolated ephedrine again. Chen and Schmidt, working with much smaller doses than Nagai, demonstrated ephedrine's value in treating heart disease and asthma. By 1927 Eli Lilly & Co. was manufacturing ephedrine on a large scale.

• Lilly Syrup No. 110, Ephedrine Sulphate, 1932
• Lilly Inhalant No. 20, Ephedrine Compound, 1932
• Swan-Myers Ephedrine Inhalant No. 66, ca. 1940

(Courtesy National Museum of American History, Smithsonian Institution)

Source: NIH: Government information at NLM Web sites is in the public domain.

Licensing

	This work is in the public domain in the United States because it is a work prepared by an officer or employee of the United States Government as part of that person’s official duties under the terms of Title 17, Chapter 1, Section 105 of the US Code. Note: This only applies to original works of the Federal Government and not to the work of any individual U.S. state, territory, commonwealth, county, municipality, or any other subdivision. This template also does not apply to postage stamp designs published by the United States Postal Service since 1978. (See § 313.6(C)(1) of Compendium of U.S. Copyright Office Practices). It also does not apply to certain US coins; see The US Mint Terms of Use.
This file has been identified as being free of known restrictions under copyright law, including all related and neighboring rights.

https://creativecommons.org/publicdomain/mark/1.0/PDMCreative Commons Public Domain Mark 1.0falsefalse